SCHEMBL4149095

SCHEMBL4149095

COC(=O)c1cc(C2=C(c3cc(Cl)ccc3O)CCC2)cnc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.54
CYP2C9 P11712 3/20 0.54
SLC6A3 Q01959 9/20 0.42
SLC6A2 P23975 4/20 0.39
MAPT P10636 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
ABL1 P00519 1/20 0.37
VEGFA P15692 1/20 0.36
FLT1 P17948 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
ALOX15 P16050 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159511 0.90 PTGER1 (0.54) PTGER1CYP2C9MAPTNPC1RAB9A
SCHEMBL4151773 0.88 PTGER1 (0.60) PTGER1CYP2C9SLC6A3SLC6A2MAPT
SCHEMBL4165872 0.88 PTGER1 (0.64) PTGER1CYP2C9MAPTL3MBTL1ALDH1A1
SCHEMBL4157965 0.86 PTGER1 (0.45) PTGER1CYP2C9SLC6A3SLC6A2MAPT
SCHEMBL4170679 0.85 PTGER1 (0.42) PTGER1CYP2C9SLC6A2MAPTLMNA
SCHEMBL4170731 0.82 PTGER1 (0.72) PTGER1CYP2C9
SCHEMBL4147587 0.80 PTGER1 (0.84) PTGER1CYP2C9CYP3A4CYP2C19
SCHEMBL4150739 0.79 PTGER1 (0.68) PTGER1CYP2C9CYP3A4CYP2C19
SCHEMBL4156020 0.77 PTGER1 (0.52) PTGER1CYP2C9MAPTL3MBTL1SMN1; SMN2
SCHEMBL4150152 0.76 PTGER1 (0.51) PTGER1CYP2C9SLC6A3MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
EP-1670763-A1 CYCLOPENTENE COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-06-21 EP disclosed
WO-2005037793-A1 CYCLOPENTENE COMPOUNDS GLAXO GROUP LIMITED (GB) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227591-A1 Cyclopentene compounds C1R, CYP1B1, ADORA2B PTGER1 246/4885CYP2C9 5/4885SLC6A3 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.